Procedures for reliable estimation of viral fitness from time-series data

In order to develop a better understanding of the evolutionary dynamics of HIV drug resistance, it is necessary to quantify accurately the in vivo fitness costs of resistance mutations. However, the reliable estimation of such fitness costs is riddled with both theoretical and experimental difficulties. Experimental fitness assays typically suffer from the shortcoming that they are based on in vitro data. Fitness estimates based on the mathematical analysis of in vivo data, however, are often questionable because the underlying assumptions are not fulfilled. In particular, the assumption that the replication rate of the virus population is constant in time is frequently grossly violated. By extending recent work of Marée and colleagues, we present here a new approach that corrects for time–dependent viral replication in time–series data for growth competition of mutants. This approach allows a reliable estimation of the relative replicative capacity (with confidence intervals) of two competing virus variants growing within the same patient, using longitudinal data for the total plasma virus load, the relative frequency of the two variants and the death rate of infected cells. We assess the accuracy of our method using computer–generated data. An implementation of the developed method is freely accessible on the Web (http://www.eco.ethz.ch/fitness.html).

[1]  E. Domingo,et al.  Drastic Fitness Loss in Human Immunodeficiency Virus Type 1 upon Serial Bottleneck Events , 1999, Journal of Virology.

[2]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[3]  M A Nowak,et al.  Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.

[4]  R de Boer,et al.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.

[5]  A. Moya,et al.  Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies , 1991, Journal of virology.

[6]  M A Nowak,et al.  Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.

[7]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[8]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[9]  D. Richman,et al.  Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. , 1990, The American journal of medicine.

[10]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[11]  Wilco Keulen,et al.  Estimating Relative Fitness in Viral Competition Experiments , 2000, Journal of Virology.

[12]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[13]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[14]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[15]  L. M. Mansky,et al.  Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. , 1996, AIDS research and human retroviruses.

[16]  J. Holland,et al.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses , 1991, Journal of virology.

[17]  Lin Chao,et al.  Fitness of RNA virus decreased by Muller's ratchet , 1990, Nature.

[18]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Larder,et al.  Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy , 1990, The Lancet.

[21]  Martin A. Nowak,et al.  The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.

[22]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[23]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[24]  A S Perelson,et al.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.

[25]  S. Leal Genetics and Analysis of Quantitative Traits , 2001 .

[26]  Michael Bunce,et al.  Evolution and transmission of stable CTL escape mutations in HIV infection , 2001, Nature.

[27]  P. Harrigan,et al.  Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro , 1998, Journal of Virology.

[28]  Sebastian Bonhoeffer,et al.  HIV results in the frame , 1995, Nature.

[29]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[30]  T. Nagylaki Introduction to Theoretical Population Genetics , 1992 .

[31]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Brahams Human immunodeficiency virus and the law. , 1987, Lancet.

[33]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[34]  Martin A. Nowak,et al.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS , 1997, Nature Medicine.

[35]  J. Martinez-Picado,et al.  Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. , 2000, Virology.

[36]  John M. Leonard,et al.  Genotypic Changes in Human Immunodeficiency Virus Type 1 Associated with Loss of Suppression of Plasma Viral RNA Levels in Subjects Treated with Ritonavir (Norvir) Monotherapy , 1998, Journal of Virology.

[37]  D. Lamarre,et al.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.

[38]  C. Benson,et al.  Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection , 1995 .

[39]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.